Emmanuelle Nicolas‐Virelizier

Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais et al. · Journal of Clinical Oncology · 2014 · 399 citations · Full text

Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Carole Soussain, Sylvain Choquet, Marie Blonski et al. · European Journal of Cancer · 2019 · 305 citations · Full text

Neuro-oncology, Primary Vitreoretinal Lymphoma, Lymphoid Neoplasia +6

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

H. Ghesquières, Marion Chevrier, Mouna Laadhari et al. · Annals of Oncology · 2019 · 226 citations · Full text

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma

Matthew J. Maurer, Emmanuel Bachy, Hervé Ghesquières et al. · American Journal of Hematology · 2016 · 219 citations · Full text

Lymphoid Neoplasia, Cancer Epidemiology, Medicine +14

PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study

Olivier Casasnovas, Réda Bouabdallah, Pauline Brice et al. · The Lancet Oncology · 2019 · 201 citations · Full text

Pet-adapted Treatment, Lymphoid Neoplasia, Medicine +5